Claude Strother says he's bagged more than 250 turkeys over the years, but he's received more attention for this one hunt.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Summit Therapeutics (SMMT) noted that Akeso (AKESF) announced ivonescimab was approved by the Chinese Health Authorities for a second ...

In response to the announcement by U.S. Senator Dick Durbin that he will not seek re-election in 2026 and will retire after more than four decades in Congress, Harold Wimmer, President and CEO of the ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health Cohort Study.

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...